Future Science OA最新文献_第6页

Dementia incidence across countries: a sex-specific ecological analysis of cancer incidence. 各国痴呆发病率：癌症发病率的性别特异性生态学分析。

IF 2.5

Future Science OA Pub Date : 2026-12-01 Epub Date: 2026-09-04 DOI: 10.1080/20565623.2026.2716616

Wenpeng You, Hui-Chen Rita Chang, Brendon Coventry, Ashlyn Sahay, Maciej Henneberg

{"title":"Dementia incidence across countries: a sex-specific ecological analysis of cancer incidence.","authors":"Wenpeng You, Hui-Chen Rita Chang, Brendon Coventry, Ashlyn Sahay, Maciej Henneberg","doi":"10.1080/20565623.2026.2716616","DOIUrl":"10.1080/20565623.2026.2716616","url":null,"abstract":"Background: Dementia incidence is rising globally with population aging and improved survival from chronic diseases. Cancer incidence may reflect longevity, diagnostic capacity, socioeconomic development, and demographic transition, but sex-specific population-level evidence on its association with dementia incidence remains limited.Methods: Country-level associations between cancer incidence in 2019 and dementia incidence in 2023 were examined separately for females and males across 204 countries. Analyses included bivariate correlations, principal component analysis, partial correlations, and forced-entry regression models adjusted for gross domestic product per capita adjusted for purchasing power parity, urbanization, reduced selection opportunity, and sex-specific life expectancy at age 60.Results: Cancer incidence was positively associated with dementia incidence in both sexes. Globally, cancer incidence correlated strongly with dementia incidence among females (r = 0.765, p < 0.001) and males (r = 0.781, p < 0.001). In adjusted models, cancer incidence remained associated with dementia incidence in females (β = 0.496, p < 0.001; adjusted R2 = 0.693) and males (β = 0.526, p < 0.001; adjusted R2 = 0.709). Incremental explained variance was larger among males.Conclusions: Cancer incidence is a sex-specific country-level correlate of dementia incidence. Findings indicate population-level co-variation, not individual-level risk or causality in aging populations worldwide.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"12 1","pages":"2716616"},"PeriodicalIF":2.5,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13556948/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148891353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The P7 peptide antagonizes bFGF-induced malignant behaviors of ovarian cancer by inhibiting MEK/ERK signaling pathway. P7肽通过抑制MEK/ERK信号通路拮抗bfgf诱导的卵巢癌恶性行为。

IF 2.1

Future Science OA Pub Date : 2026-12-01 Epub Date: 2026-01-21 DOI: 10.1080/20565623.2026.2615619

Ziying Yang, Wen Wei, Daolin Nie, Menglei Zhang, Qiong Chen

{"title":"The P7 peptide antagonizes bFGF-induced malignant behaviors of ovarian cancer by inhibiting MEK/ERK signaling pathway.","authors":"Ziying Yang, Wen Wei, Daolin Nie, Menglei Zhang, Qiong Chen","doi":"10.1080/20565623.2026.2615619","DOIUrl":"10.1080/20565623.2026.2615619","url":null,"abstract":"Background: Ovarian cancer (OC) is a highly invasive malignancy with poor prognosis, underscoring the need for novel therapeutic strategies. Basic fibroblast growth factor (bFGF) promotes OC progression by activating the MEK/ERK signaling pathway, enhancing tumor cell proliferation, migration, and invasion. P7 peptide is a novel peptide with potential antitumor effects, though its mechanism of action remains unclear. This study investigates whether P7 peptide inhibits bFGF-induced OC progression via suppression of the MEK/ERK pathway.Methods: Human OC Anglne cells were treated with varying concentrations of bFGF and P7 peptide. Cell proliferation was measured using CCK-8 assays, while RT-PCR and Western blot analyses evaluated the expression of uPA, MMP2, and E-cadherin, along with MEK/ERK pathway activation. Cell migration and invasion were assessed via wound healing and Transwell assays.Results: bFGF (30 ng/mL, 48 h) significantly enhanced cell proliferation and invasive behavior, alongside upregulation of uPA and MMP2 and reduced E-cadherin expression. P7 peptide (16 μM, 48 h) effectively reversed these effects and inhibited MEK/ERK phosphorylation.Conclusion: These findings suggest that P7 peptide suppresses bFGF-mediated OC progression by targeting the MEK/ERK pathway, supporting its potential as a novel therapeutic agent in OC.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"12 1","pages":"2615619"},"PeriodicalIF":2.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12826741/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146009918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

"Does the dose of hydroxyurea correlate with shorter hospital stay and higher fetal hemoglobin levels in patients with sickle cell disease?" “羟基脲的剂量是否与镰状细胞病患者更短的住院时间和更高的胎儿血红蛋白水平相关？”

IF 2.1

Future Science OA Pub Date : 2026-12-01 Epub Date: 2026-01-06 DOI: 10.1080/20565623.2025.2610223

Musa Fares Alzahrani, Abdulaziz Albacker, Abdulmajeed Alshabanat, Maram Alharbi, Jawahir Abuhaimed, Nouran Arnous, Yara Alzahrani, Hind Aloraier, Maha Alamri, Rawan Altamimi, Ghazi Alotaibi, Sarah Sewaralthahab, Fatima Alshalti, Ibrahim Alrumaih, Ahmad Jamal, Farjah Algahtani, Aamer Aleem

{"title":"\"Does the dose of hydroxyurea correlate with shorter hospital stay and higher fetal hemoglobin levels in patients with sickle cell disease?\"","authors":"Musa Fares Alzahrani, Abdulaziz Albacker, Abdulmajeed Alshabanat, Maram Alharbi, Jawahir Abuhaimed, Nouran Arnous, Yara Alzahrani, Hind Aloraier, Maha Alamri, Rawan Altamimi, Ghazi Alotaibi, Sarah Sewaralthahab, Fatima Alshalti, Ibrahim Alrumaih, Ahmad Jamal, Farjah Algahtani, Aamer Aleem","doi":"10.1080/20565623.2025.2610223","DOIUrl":"10.1080/20565623.2025.2610223","url":null,"abstract":"Background & aims: Sickle cell disease (SCD) leads to recurrent vaso-occlusive crises (VOC) and hospitalizations, imposing a substantial healthcare burden. Hydroxyurea (HU) is known to reduce VOC frequency and hospitalization rates in SCD; however, data comparing the impact of different HU doses on length of stay (LOS) and clinical outcomes in adults are limited.Methods: This retrospective study assessed the effect of high- versus low-dose HU on LOS among adults with SCD admitted to medical wards. Secondary endpoints included VOC frequency and hemoglobin electrophoresis findings. Pearson's chi-square and Mann-Whitney tests were used, with significance set at p < 0.05.Results: A total of 141 patients were analyzed (26 on low-dose, 115 on high-dose HU), with a median age of 31 years; 52.5% were female. The overall median LOS was 3 days (IQR 1-10). The low-dose group had a significantly longer median LOS (7 days [IQR 7-9]) compared with the high-dose group (2 days [IQR 2-3]; p < 0.001). Higher HU doses were also associated with improved Hgb F% and Hgb S% (p < 0.001), while annual VOC rates showed no significant difference (p = 0.132).Conclusion: High-dose HU was linked to shorter hospital stays and favorable hematologic outcomes in adults with SCD.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"12 1","pages":"2610223"},"PeriodicalIF":2.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12785233/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145911334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical efficacy of 2-week and 3-week albumin-bound paclitaxel therapy for advanced pancreatic cancer. 2周和3周白蛋白结合紫杉醇治疗晚期胰腺癌的临床疗效观察。

IF 2.1

Future Science OA Pub Date : 2026-12-01 Epub Date: 2026-01-26 DOI: 10.1080/20565623.2026.2617117

Zhimin Su, Jiana Jiang, Feng Shen, Zhiyong Li

{"title":"Clinical efficacy of 2-week and 3-week albumin-bound paclitaxel therapy for advanced pancreatic cancer.","authors":"Zhimin Su, Jiana Jiang, Feng Shen, Zhiyong Li","doi":"10.1080/20565623.2026.2617117","DOIUrl":"https://doi.org/10.1080/20565623.2026.2617117","url":null,"abstract":"Objective: We aim to compare the clinical efficacy and safety of albumin-bound paclitaxel (nab-PTX) (125 mg/m2, q2w) for two weeks and (125 mg/m2, d1, d8, q3w) for three weeks in the first-line treatment of advanced pancreatic cancer.Methods: The medical records of patients with advanced pancreatic cancer who received nab-PTX for 2 weeks and 3 weeks, combined with gemcitabine, from July 2018 to January 2023, were retrospectively analyzed. The efficacy and adverse reactions of the two groups of patients were compared.Result: A total of 64 patients were included. The median progression-free survival (mPFS) of the 2-week group was 5.6 months, while the 3-week group was 7.8 months. The median overall survival (mOS) of the 2-week group was 14.0 months, while the 3-week group was 14.7 months. The multivariate analysis showed that a physical fitness status score of 0-1 was an independent factor with better OS, while metastatic sites ≥ 3 were related to poor OS. The incidence of leukopenia or neutropenia, neurotoxicity, fatigue, and poor appetite in the 2-week group was lower than that in the 3-week group.Conclusion: The clinical efficacy of nab-PTX in the 2-week and dose intensive 3 week did not show significant difference, but the 2-week treatment group had better tolerance and safety.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"12 1","pages":"2617117"},"PeriodicalIF":2.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146051578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Before depression in diabetes is attributed to polyneuropathy, all other causes must be ruled out. 在将糖尿病抑郁症归因于多发性神经病变之前，必须排除所有其他原因。

IF 2.1

Future Science OA Pub Date : 2026-12-01 Epub Date: 2025-12-22 DOI: 10.1080/20565623.2025.2603881

Josef Finsterer

引用次数: 0

Why are we still missing the pain? Rethinking diabetic neuropathy in primary care - lessons from the REGENERAR study. 为什么我们还在想念痛苦？重新思考初级保健中的糖尿病神经病变——来自REGENERAR研究的教训。

IF 2.1

Future Science OA Pub Date : 2026-12-01 Epub Date: 2025-12-24 DOI: 10.1080/20565623.2025.2605943

Antonio Alcántara Montero

引用次数: 0

Early pregnancy ultrasound as a tool for detecting fetal structural abnormalities: insights from a retrospective study. 早期妊娠超声作为检测胎儿结构异常的工具：来自回顾性研究的见解。

IF 2.1

Future Science OA Pub Date : 2026-12-01 Epub Date: 2026-03-19 DOI: 10.1080/20565623.2026.2644323

Georges Yared, Jihad Al Hassan, Charlotte El Hajjar, Ahmad El Moghrabi, Karl Khalil, Kariman Ghazal

{"title":"Early pregnancy ultrasound as a tool for detecting fetal structural abnormalities: insights from a retrospective study.","authors":"Georges Yared, Jihad Al Hassan, Charlotte El Hajjar, Ahmad El Moghrabi, Karl Khalil, Kariman Ghazal","doi":"10.1080/20565623.2026.2644323","DOIUrl":"https://doi.org/10.1080/20565623.2026.2644323","url":null,"abstract":"Background: On a global level, congenital anomalies remain a major cause of childhood illness and mortality. While international guidelines emphasize second-trimester ultrasound for anomaly screening, there is growing evidence that important structural abnormalities can already be identified in the first trimester. This study examined the value of early ultrasound in detecting fetal anomalies and its effect on pregnancy outcomes.Methods: We carried out a retrospective review of 159 pregnancies seen at a private antenatal clinic in Beirut. Maternal demographics, obstetric history, and neonatal outcomes were recorded. All women underwent a first-trimester ultrasound scan, and findings were analyzed alongside pregnancy outcomes. Statistical tests included chi-square, Fisher's exact, and t-tests.Results: Congenital anomalies were detected in 31 pregnancies (19.5%), with a birth prevalence of 14.2% (20/141 live births). They most commonly involved the central nervous system (CNS) and the heart. Among affected cases, 61% ended in prenatal or early neonatal death. Women who took folic acid before conception had a significantly lower risk of malformations compared with those who started supplementation later.Conclusion: First-trimester ultrasound is a valuable tool for the early recognition of fetal anomalies and can inform timely management. Pre-conception folic shows a protective association. Larger, multicenter studies are needed to validate these findings.Data collection: The dataset used in this study was owned by the private antenatal referral clinic where the patients received routine clinical care. Permission to access and use the anonymized was obtained in the clinic. Moreover, data were extracted in accordance with institutional policies and patient consent.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"12 1","pages":"2644323"},"PeriodicalIF":2.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147485465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ozone therapy by rectal insufflation in long COVID syndrome: a preliminary study with thermographic evaluation and quality of life measurement. 直肠注入臭氧治疗长冠综合征：热成像评价和生活质量测量的初步研究。

IF 2.5

Future Science OA Pub Date : 2026-12-01 Epub Date: 2026-07-20 DOI: 10.1080/20565623.2026.2704605

Raquel Sacristan Perez, Maria José Martínez Vivas, Silvia Menéndez-Cepero, Alessio Cabizosu, Francisco-Javier Hidalgo Tallón

{"title":"Ozone therapy by rectal insufflation in long COVID syndrome: a preliminary study with thermographic evaluation and quality of life measurement.","authors":"Raquel Sacristan Perez, Maria José Martínez Vivas, Silvia Menéndez-Cepero, Alessio Cabizosu, Francisco-Javier Hidalgo Tallón","doi":"10.1080/20565623.2026.2704605","DOIUrl":"10.1080/20565623.2026.2704605","url":null,"abstract":"Introduction: Post-acute coronavirus disease 2019 syndrome (PACS) is a multisystemic clinical condition that clinically starting weeks or even months after acute SARS-CoV-2 (COVID 19) infections. The objective of this study was to explore change in quality of life, mechanical force and metabolic activity after ozone therapy treatment.Methods: A preliminary clinical open label study was carried out. Twenty-three patients diagnosed with PACS more than 5 months ago participated in the study. Thermography, Handgrip test and Quality of life scale SF12 were used to analyze the effects of ozone therapy on these patients.Results: Related to the Handgrip test, a significant improvement was recorded in T0-T1 time interval (p = 0.0003; d 0.88), but in T1-T2 time variation was not statistically significant (p = 0.957). About the SF-12 test, a significant difference was also found in both the PCS (p = 0.0038; d = 0.67) and the MCS (p = 0.0088, d = 0.60) in T0-T1 time, but not in T1-T2 for either the PCS (p = 0.5933) or the MCS (p = 0.3917). Finally, regarding temperature, statistically significant differences were observed in the T0-T1 time interval (p = 0.0465, d = 0.44) but not between T1 and T2 (p = 0.1038). No significant differences between the sexes were observed for any of the four parameters.Conclusion: Our results confirmed that clinical ozone could be a potentially useful drug in improving the strength, quality of life and basal metabolism in patients with long COVID. However, we believe that further studies and larger sample sizes are needed to corroborate and support the results obtained in this preliminary trial.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"12 1","pages":"2704605"},"PeriodicalIF":2.5,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13390503/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148535746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Global burden and trends of stomach cancer, Colon and rectum cancer, peptic ulcer disease, and gastritis and duodenitis from 1990 to 2021: a systematic analysis for the global burden of disease study 2021. 1990 - 2021年胃癌、结肠癌和直肠癌、消化性溃疡疾病、胃炎和十二指肠炎的全球负担和趋势：对2021年全球疾病负担研究的系统分析

IF 2.5

Future Science OA Pub Date : 2026-12-01 Epub Date: 2026-07-08 DOI: 10.1080/20565623.2026.2697986

Quan-Yao Li, Hui Liu, Wen-Chao Qiu, Ying Lu, Xi Li, Min-Zhi Zhuang, Ying Zhu, Jun Shi

{"title":"Global burden and trends of stomach cancer, Colon and rectum cancer, peptic ulcer disease, and gastritis and duodenitis from 1990 to 2021: a systematic analysis for the global burden of disease study 2021.","authors":"Quan-Yao Li, Hui Liu, Wen-Chao Qiu, Ying Lu, Xi Li, Min-Zhi Zhuang, Ying Zhu, Jun Shi","doi":"10.1080/20565623.2026.2697986","DOIUrl":"10.1080/20565623.2026.2697986","url":null,"abstract":"Background: Geographical disparities are evident in the burden of digestive system diseases. To date, however, a comparative analysis that simultaneously examines the burden of common digestive cancers alongside non-malignant conditions using the most recent GBD 2021 data is lacking. A comprehensive global assessment of the burden of digestive system diseases is therefore warranted.Methods: This study analyzed incidence, prevalence, mortality, and DALYs of four digestive system diseases from the GBD 2021 database. The incidence, prevalence, mortality, and DALYs were further examined across age groups, sexes, and regions. The ASIR, ASPR, ASMR, ASDR, and EAPC were used to evaluate the disease burden.Results: In 2021, gastritis and duodenitis exhibited the highest ASIR and ASPR, whereas colon and rectum cancer presented the highest ASMR and ASDR. From 1990 to 2021, the ASIR and ASPR of colon and rectum cancer demonstrated an upward trend, while its ASMR and ASDR declined. By contrast, all metrics for stomach cancer, peptic ulcer disease, and gastritis and duodenitis showed declining trends.Conclusion: The global burden of digestive diseases continues to pose a substantial public health challenge. Greater attention should be directed toward high-risk factors, early screening, and effective prevention and treatment strategies.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"12 1","pages":"2697986"},"PeriodicalIF":2.5,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13348945/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148404282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A deceptive fungating breast mass: giant fibroadenoma with multiple epidermal inclusion cysts mimicking malignancy. 假真菌性乳腺肿块：巨大纤维腺瘤伴多发表皮包涵囊肿，形似恶性肿瘤。

IF 2.5

Future Science OA Pub Date : 2026-12-01 Epub Date: 2026-09-05 DOI: 10.1080/20565623.2026.2728652

Ghaith B Heilat, Amjad Z Alrosan, Reem Mohammad Muhsen, Dania Abuhashish, Rama Matalgah, Saad Tayyem, Mahfouz Ktaifan, Maha M Gharaibeh

{"title":"A deceptive fungating breast mass: giant fibroadenoma with multiple epidermal inclusion cysts mimicking malignancy.","authors":"Ghaith B Heilat, Amjad Z Alrosan, Reem Mohammad Muhsen, Dania Abuhashish, Rama Matalgah, Saad Tayyem, Mahfouz Ktaifan, Maha M Gharaibeh","doi":"10.1080/20565623.2026.2728652","DOIUrl":"10.1080/20565623.2026.2728652","url":null,"abstract":"Aims: To describe a giant ulcerating fibroadenoma mimicking malignancy and highlight diagnostic uncertainty from discordant clinical, imaging, and biopsy findings.Patients and methods: A 22-year-old woman presented with an approximately 10 cm fungating, ulcerated right-breast mass complicated by methicillin-resistant Staphylococcus aureus infection. Multiple core biopsies showed fibroadenoma, despite rapid progression raising concern for phyllodes tumor or malignancy. Multidisciplinary review supported a staged breast-preserving approach.Results: The mass was enucleated with preservation of the nipple-areolar complex. Histopathology confirmed giant fibroadenoma with multiple epidermal inclusion cysts, cyst rupture, keratin-associated inflammation, and a foreign-body giant-cell reaction. Earlier biopsy material showed an epidermal component before clinical deterioration. Biopsy-related disruption of this preexisting component, together with inflammation, infection, cyst rupture, and wound breakdown, was considered a possible contributor to the fungating presentation; the exact sequence was uncertain. Histology showed focal superficial-margin involvement at the ulcerated/fungating surface. At six months, there was no clinical or ultrasonographic evidence of recurrence.Conclusions: Giant fibroadenomas may mimic phyllodes tumor or breast malignancy. Clinicoradiological-pathological correlation and multidisciplinary planning can support breast-preserving management despite an alarming presentation when tissue diagnosis remains benign.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"12 1","pages":"2728652"},"PeriodicalIF":2.5,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13556946/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148896964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0